cor2ed
engage checkpoint medical linkedin twitter
bg

Understand the MoA of PARP inhibitors and targeting DNA Damage Response (DDR)

Understand the MoA of PARP inhibitors and targeting DNA Damage Response (DDR)

Dr. Robert L. Coleman, Prof. Simon Boulton

A short video explaining the concept of DDR, the role of Homologous Recombination Repair (HRR) in DNA repair and the impact of BRCA1 and BRCA2 mutations. It explores PARP inhibitors as the proof of concept for targeting DDR, demonstrating how they work and their clinical benefit.

Portrait of Robert L. Coleman
Dr. Robert L. Coleman

Gynaecologic Oncologist

US Oncology Research

United States (US)

Portrait of Simon Boulton
Prof. Simon Boulton

Senior Scientist

Francis Crick Institute

United Kingdom (UK)

preview next

time Video | open 5 min | Sep 2021

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

 

Other programmes of interest